Mangano Anna Maria, Pacilio Massimiliano, Ialongo Pasquale, Semprebene Alessandro, Ventroni Guido, Mango Lucio
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy.
Medical Physics Unit, "Policlinico Umberto I" University Hospital, 00161 Rome, Italy.
Diagnostics (Basel). 2018 Feb 27;8(1):18. doi: 10.3390/diagnostics8010018.
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.
在此，我们报告一例64岁男性患者，诊断为去势抵抗性前列腺癌（CRPC）伴骨转移，接受阿比特龙泼尼松/泼尼松龙联合二氯化镭治疗，治疗后骨扫描显示缓解，但随后骨转移复发。我们还讨论了根据剂量测定考虑，如果在副作用无显著增加的情况下，是否有可能通过以相同剂量或更高剂量给予其他疗程，在计划的六个给药周期内继续进行二氯化镭治疗。
